verapamil has been researched along with benazepril in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Arita, M; Frohlich, ED; Horinaka, S; Komatsu, K | 1 |
Hilleman, DE; Mohiuddin, SM; Ryschon, KL; Wurdeman, RL | 1 |
Bacher, P; Champion, A; Fakouhi, K; Tian, M; Toto, RD | 1 |
2 review(s) available for verapamil and benazepril
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Drug Combinations; Humans; Hypertension; Lisinopril; Treatment Outcome; Verapamil | 1999 |
1 trial(s) available for verapamil and benazepril
Article | Year |
---|---|
Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Synergism; Drug Therapy, Combination; Female; Humans; Indoles; Male; Middle Aged; Prospective Studies; Proteinuria; Treatment Outcome; Verapamil | 2008 |
2 other study(ies) available for verapamil and benazepril
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Reversal of left ventricular hypertrophy with different classes of drugs causes differing ventricular biochemical changes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Celiprolol; Collagen; Hypertension; Hypertrophy, Left Ventricular; Male; Proteins; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA; Verapamil | 1993 |